EUCTR2012-000459-15-ES进行中（未招募）1 期
Phase IV/II open label study for the early evaluation of the response to treatment with Cisplatin, Gemcitabine and Bevacizumab in patientes with advanced or metastatic non small cell lung cancer. - IMPACT
Fundació Clínic per la Recerca Biomèdica0 个研究点开始时间: 2012年3月29日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 open label study in MPS IIIB subjects to investigate the long term safety and effect of SBC-103 given by IV infusion.Mucopolysaccharidosis III, type B (MPS IIIB), Sanfilippo BMedDRA version: 19.0 Level: LLT Classification code 10056918 Term: Sanfilippo's syndrome System Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 19.0 Level: PT Classification code 10056890 Term: Mucopolysaccharidosis III System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-001983-20-GBAlexion Pharmaceuticals, Inc3
进行中（未招募）
1 期
Post-marketing study of safety and efficacy of GARDASIL in young Japanese women.Human Papillomavirus infectionEUCTR2015-002932-42-Outside-EU/EEAMSD K.K., a subsidiary of Merck & Co., Inc1,000
进行中（未招募）
1 期
A phase I/ II study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLCSquamous Cell Non-Small Cell Lung Cancerandadvanced endometrial cancerMedDRA version: 19.0Level: LLTClassification code 10014743Term: Endometrial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10025120Term: Lung squamous cell carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10071533Term: Lung squamous cell carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10014747Term: Endometrial carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10025124Term: Lung squamous cell carcinoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10014745Term: Endometrial carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10014749Term: Endometrial carcinoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10014751Term: Endometrial carcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10025125Term: Lung squamous cell carcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10014750Term: Endometrial carcEUCTR2016-001352-21-ESAbility Pharmaceuticals, S80
进行中（未招募）
不适用
An exploratory, open label phase II study to evaluate the feasibility of contrast-enhanced MRI for measurement of perfusion in squamous cell cancer of the head & neck: comparison of the intravascular contrast agent Vasovist vs. the conventional contrast agent Magnevist - Vasovist in head & neck tumorsPatients of both gender are eligible for this study in case they present with the diagnosis of a primary squamous cell carcinoma of the head & neck after Magnevist-enhanced MRI, are scheduled for tumor biopsy or tumor surgery for clinical reasons, and meet all in- and exclusion criteria.MedDRA version: 9.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2007-001802-25-DEJohann-Wolfgang Goethe-Universität
进行中（未招募）
1 期
A clinical study to assess how safe and tolerable the therapy EI-201 is, how it induces an immune response and how it affects the tumor in cancer patients with a human papillomavirus 16 positive cancerEUCTR2021-004277-31-BEeTheRNA immunotherapies NV66